NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Press Enter or click the Search button to begin your search.

Back to Results
Effects of Intrarenal and Intravenous Infusion of the Phosphodiesterase 3 Inhibitor Milrinone on Renin SecretionWe have reported that administration of the phosphodiesterase III inhibitor milrinone increases renin secretion in conscious rabbits. The aim of the present study was to determine if the increase in renin secretion results from a direct renal action of milrinone, or from an indirect extrarenal effect of the drug. This was accomplished by comparing the effects of intrarenal and intravenous infusion of graded doses of milrinone on plasma renin activity in unilaterally nephrectomized conscious rabbits. Milrinone was infused into the renal artery in doses of 0.01, 0.1 and 1.0 micro-g/kg/min, and intravenously in the same rabbits in doses of 0.01, 0.1, 1.0 and 10 micro-g/kg/min. Each dose was infused for 15 min. No intrarenal dose of milrinone altered plasma renin activity or arterial pressure, although at the highest dose, there was a small increase in heart rate. Intravenous infusion of milrinone at 1.0 micro-g/kg/min increased plasma renin activity to 176 +/- 55% of the control value (P less than 0.05). Heart rate increased but arterial pressure did not change. Intravenous infusion of milrinone at 1O micro-g/kg/min increased plasma renin activity to 386 +/- 193% of control in association with a decrease in arterial pressure and an increase in heart rate. These results confirm that milrinone increases renin secretion, and indicate that the stimulation is due to an extrarenal effect of the drug.
Document ID
19980008090
Acquisition Source
Ames Research Center
Document Type
Reprint (Version printed in journal)
Authors
Kumagai, Kazuhiro
(California Univ. San Francisco, CA United States)
Reid, Ian A.
(California Univ. San Francisco, CA United States)
Date Acquired
September 6, 2013
Publication Date
January 1, 1994
Publication Information
Publication: Pharmacol. (Life Sci. Adv.)
Volume: 13
Subject Category
Aerospace Medicine
Report/Patent Number
NAS 1.26:205260
NASA-CR-205260
Report Number: NAS 1.26:205260
Report Number: NASA-CR-205260
Funding Number(s)
CONTRACT_GRANT: NAG2-779
Distribution Limits
Public
Copyright
Work of the US Gov. Public Use Permitted.
No Preview Available